549 - A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia.

Presenting Author(s)

• 

  Loren G. Miller, MD MPH

  Professor of Medicine
  Lundquist Institute at Harbor-UCLA Medical Center
  Los Angeles, CA, United States

  Slides

Co-Author(s)

• SK

  Stacey Kolar, PHD

  Director, Clinical Pharmacology
  Armata Pharmaceuticals
  Los Angeles, California, United States
• JS

  John Sanders, MD

  Chief, Infectious Disease
  Wake Forest University
  Winston, North Carolina, United States
• 

  John C. Williamson, PharmD (he/him/his)

  Associate Professor
  Wake Forest School of Medicine
  Winston-Salem, NC, United States
• PA

  Paul R. Allyn, MD

  Dr.
  UCLA
  Los Angeles, California, United States
• JB

  Jihoon Baang, MD

  Clinical Associate Professor
  University of Michigan Medical Center
  Ann Arbor, Michigan, United States
• PR

  Paul F. Riska, MD

  Montefiore Medical Center
  Bronx, New York, United States
• SA

  Saima Aslam, MD

  Univesity of California at San Diego
  San Diego, California, United States
• GA

  George J. Alangaden, MD

  Infectious Diseases Transplant Fellowship, Program Director
  Henry Ford Health
  Detroit, Michigan, United States
• JW

  Jane Wainaina, MD

  Vice Chair for Quality
  Froedtert Hospital & Medical College of Wisconsin
  Milwaukee, Wisconsin, United States
• 

  Colleen S. Kraft, MD, MSc

  Associate Professor
  Emory University
  Atlanta, GA, United States
• NM

  Nirja Mehta, MD

  Resident Physician
  Emory University
  Atlanta, GA, United States
• DA

  Deena Altman, MD

  Assistant Professor
  Icahn School of Medicine at Mount Sinai
  New York, New York, United States
• GW

  Gary P. Wang, MD, PHD

  Chief of the Division of Infectious Diseases and Global Medicine
  University of Florida
  Gainesville, Florida, United States
• MM

  Mehdi Mirsaeidi, MD, MPH

  Chief, Division of Pulmonary, Critical Care and Sleep Medicine
  University of Florida Health - Jacksonville
  Jacksonville, Florida, United States
• DP

  D. Alexander Perry, MD, MPH

  Co-Associate Clinical Director
  University of Arizona - Banner Health
  Tucson, Arizona, United States
• 

  Jose A. Vazquez, MD, FACP, FIDSA

  Professor of Medicine
  Medical College of Georgia at Augusta University
  Augusta, GA, United States
• LN

  Lindsay Nicholson, MD

  Infectious Disease Specialist
  Rocky Mountain Regional Veterans Administration Medical Center
  Aurora, Colorado, United States
• JI

  Jonathan Iredell, MBBS, PhD

  Director, Centre for Infectious Diseases and Microbiology
  (2) Microbial Genomics Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, ICPMR Westmead, NSW Australia (3) University of Sydney, Sydney, NSW Australia (4) Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Westmead Hospital, NSW Australia
  Westmead, New South Wales, Australia
• PK

  Pierre Kyme, PHD

  Chief Business Officer
  Armata Pharmaceuticals
  Los Angeles, California, United States
• DB

  Deborah Birx, MD

  Chief Executive Officer
  Armata Pharmaceuticals
  Los Angeles, California, United States
• 

  Vance G. Fowler, MD, MHS

  Professor of Medicine
  Duke University Medical Center
  Durham, NC, United States